These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 2001455)

  • 21. The effect of the antisickling compound GBT1118 on the permeability of red blood cells from patients with sickle cell anemia.
    Al Balushi H; Dufu K; Rees DC; Brewin JN; Hannemann A; Oksenberg D; Lu DC; Gibson JS
    Physiol Rep; 2019 Mar; 7(6):e14027. PubMed ID: 30916477
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
    Vichinsky E; Hoppe CC; Ataga KI; Ware RE; Nduba V; El-Beshlawy A; Hassab H; Achebe MM; Alkindi S; Brown RC; Diuguid DL; Telfer P; Tsitsikas DA; Elghandour A; Gordeuk VR; Kanter J; Abboud MR; Lehrer-Graiwer J; Tonda M; Intondi A; Tong B; Howard J;
    N Engl J Med; 2019 Aug; 381(6):509-519. PubMed ID: 31199090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.
    Oksenberg D; Dufu K; Patel MP; Chuang C; Li Z; Xu Q; Silva-Garcia A; Zhou C; Hutchaleelaha A; Patskovska L; Patskovsky Y; Almo SC; Sinha U; Metcalf BW; Archer DR
    Br J Haematol; 2016 Oct; 175(1):141-53. PubMed ID: 27378309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Established and experimental treatments for sickle cell disease.
    De Franceschi L; Corrocher R
    Haematologica; 2004 Mar; 89(3):348-56. PubMed ID: 15020275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Voxelotor does not inhibit sickle hemoglobin fiber formation upon complete deoxygenation.
    Worth EH; Fugate MK; Ferrone FA
    Biophys J; 2023 Jul; 122(13):2782-2790. PubMed ID: 37270670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hemoglobin S polymerization: primary determinant of the hemolytic and clinical severity of the sickling syndromes.
    Brittenham GM; Schechter AN; Noguchi CT
    Blood; 1985 Jan; 65(1):183-9. PubMed ID: 3965046
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A structure-guided approach to ameliorate sickle cell disease.
    Richter-Addo GB
    Acta Crystallogr D Struct Biol; 2018 Nov; 74(Pt 11):1039-1040. PubMed ID: 30387762
    [No Abstract]   [Full Text] [Related]  

  • 28. Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin.
    Safo MK; Kato GJ
    Hematol Oncol Clin North Am; 2014 Apr; 28(2):217-31. PubMed ID: 24589263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Triazole Disulfide Compound Increases the Affinity of Hemoglobin for Oxygen and Reduces the Sickling of Human Sickle Cells.
    Nakagawa A; Ferrari M; Schleifer G; Cooper MK; Liu C; Yu B; Berra L; Klings ES; Safo RS; Chen Q; Musayev FN; Safo MK; Abdulmalik O; Bloch DB; Zapol WM
    Mol Pharm; 2018 May; 15(5):1954-1963. PubMed ID: 29634905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overview of pathophysiology and rationale for treatment of sickle cell anemia.
    Rodgers GP
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):2-7. PubMed ID: 9317195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physiologic and rheologic effects of the antisickling agent ethacrynic acid and its N-butylated derivative on normal and sickle erythrocytes.
    Orringer EP; Blythe DS; Whitney JA; Brockenbrough S; Abraham DJ
    Am J Hematol; 1992 Jan; 39(1):39-44. PubMed ID: 1536139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. O2 dependence of K+ transport in sickle cells: the effect of different cell populations and the substituted benzaldehyde 12C79.
    Gibson JS; Khan A; Speake PF; Ellory JC
    FASEB J; 2001 Mar; 15(3):823-32. PubMed ID: 11259401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice.
    Shrestha A; Chi M; Wagner K; Malik A; Korpik J; Drake A; Fulzele K; Guichard S; Malik P
    Blood Adv; 2021 May; 5(9):2385-2390. PubMed ID: 33944896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anion transport in normal erythrocytes, sickle red cells, and ghosts in relation to hemoglobins and magnesium.
    Teti D; Venza I; Crupi M; Busà M; Loddo S; Romano L
    Arch Biochem Biophys; 2002 Jul; 403(2):149-54. PubMed ID: 12139963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease.
    Gopalsamy A; Aulabaugh AE; Barakat A; Beaumont KC; Cabral S; Canterbury DP; Casimiro-Garcia A; Chang JS; Chen MZ; Choi C; Dow RL; Fadeyi OO; Feng X; France SP; Howard RM; Janz JM; Jasti J; Jasuja R; Jones LH; King-Ahmad A; Knee KM; Kohrt JT; Limberakis C; Liras S; Martinez CA; McClure KF; Narayanan A; Narula J; Novak JJ; O'Connell TN; Parikh MD; Piotrowski DW; Plotnikova O; Robinson RP; Sahasrabudhe PV; Sharma R; Thuma BA; Vasa D; Wei L; Wenzel AZ; Withka JM; Xiao J; Yayla HG
    J Med Chem; 2021 Jan; 64(1):326-342. PubMed ID: 33356244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells.
    Abdulmalik O; Safo MK; Chen Q; Yang J; Brugnara C; Ohene-Frempong K; Abraham DJ; Asakura T
    Br J Haematol; 2005 Feb; 128(4):552-61. PubMed ID: 15686467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic enhancement of polymerization of recombinant sickle hemoglobin mutants: implications for transgenic mouse model for sickle cell anemia.
    Li X; Mirza UA; Chait BT; Manning JM
    Blood; 1997 Dec; 90(11):4620-7. PubMed ID: 9373274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative prediction of erythrocyte sickling for the development of advanced sickle cell therapies.
    Lu L; Li Z; Li H; Li X; Vekilov PG; Karniadakis GE
    Sci Adv; 2019 Aug; 5(8):eaax3905. PubMed ID: 31457104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of BW12C on oxygen affinity of haemoglobin in sickle-cell disease.
    Keidan AJ; Franklin IM; White RD; Joy M; Huehns ER; Stuart J
    Lancet; 1986 Apr; 1(8485):831-4. PubMed ID: 2870317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry.
    Rab MAE; van Oirschot BA; Bos J; Kanne CK; Sheehan VA; van Beers EJ; van Wijk R
    J Vis Exp; 2019 Nov; (153):. PubMed ID: 31762454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.